Search results for "Neutro"

showing 10 items of 2997 documents

Arginase 1 Is a Marker of Myeloid-Mediated Immunosuppression with Prognostic Meaning in Classic Hodgkin Lymphoma

2016

Abstract Purpose : Neutrophilia is hallmark of classic Hodgkin Lymphoma (cHL), but its precise characterization remains elusive. We aimed at investigating the immunosuppressive role of high-density neutrophils in HL. Experimental design : First, N-HL function was evaluated in vitro, showing increased arginase (Arg-1) expression and activity compared to healthy subjects. Second, we measured serum level of Arg-1 (s-Arg-1) by ELISA in two independent, training (N=40) and validation (N=78) sets. Results : s-Arg-1 was higher in patients with advanced stage (p=0.045), B-symptoms (p=0.0048) and a positive FDG-PET scan after two cycles of chemotherapy (PET-2, p=0.012). Baseline levels of s-Arg-1 &g…

0301 basic medicineOncologymedicine.medical_specialtyPrognostic variableMyeloidmedicine.medical_treatmentImmunologyBiochemistry03 medical and health sciencesInternal medicinemedicineProgression-free survivalChemotherapybusiness.industryImmunosuppressionCell BiologyHematologymedicine.diseaseChemotherapy regimenNeutrophiliaLeukemia030104 developmental biologymedicine.anatomical_structureImmunologymedicine.symptombusinessBlood
researchProduct

Monitoring blood biomarkers to predict nivolumab effectiveness in NSCLC patients

2019

Background: We investigated whether early dynamic changes of circulating free (cfDNA) levels as well as the neutrophil to lymphocyte ratio (NLR) could predict nivolumab effectiveness in pretreated patients with advanced non-small cell lung cancer (NSCLC). Methods: A total of 45 patients receiving nivolumab 3 mg/kg every 2 weeks were enrolled. Patients underwent a computed tomography scan and responses were evaluated by the response evaluation criteria in solid tumors. Peripheral blood samples were obtained from the patients and the cfDNA level as well as the NLR were assessed. Time to progression (TTP) and overall survival (OS) were determined. Results: Patients with increased cfDNA >20%…

0301 basic medicineOncologymedicine.medical_specialtySettore MED/06 - Oncologia Medicamedicine.medical_treatmentnon-small cell lung cancer (NSCLC)Circulating free DNA (cfDNA)blood-based biomarkers; Circulating free DNA (cfDNA); immunotherapy; neutrophil to lymphocyte ratio (NLR); non-small cell lung cancer (NSCLC)lcsh:RC254-28203 medical and health sciences0302 clinical medicineInternal medicinemedicineNeutrophil to lymphocyte ratioOriginal Researchblood-based biomarkerbusiness.industryBlood based biomarkersblood-based biomarkersImmunotherapylcsh:Neoplasms. Tumors. Oncology. Including cancer and carcinogensmedicine.diseaseneutrophil to lymphocyte ratio (NLR)non-small cell lung cancer (NSCLC)030104 developmental biologyOncologyBlood biomarkers030220 oncology & carcinogenesisimmunotherapyNivolumabbusiness
researchProduct

Propeptide glycosylation and galectin‐3 binding decrease proteolytic activation of human proMMP‐9/progelatinase B

2019

Matrix metalloproteinases (MMPs) are secreted as proenzymes, containing propeptides that interact with the catalytic zinc, thereby controlling MMP activation. The MMP‐9 propeptide is unique in the MMP family because of its post‐translational modification with an N‐linked oligosaccharide. ProMMP‐9 activation by MMP‐3 occurs stepwise by cleavage of the propeptide in an aminoterminal (pro‐AT) and carboxyterminal (pro‐CT) peptide. We chemically synthesized aglycosyl pro‐AT and pro‐CT and purified recombinant glycosylated pro‐ATS f−9. First, we report new cleavage sites in the MMP‐9 propeptide by MMP‐3 and neutrophil elastase. Additionally, we demonstrated with the use of western blot analysis a…

0301 basic medicinePNGase FN-linked glycosylationGlycosylationGlycosylationmatrix metalloproteinase‐9Galectin 3GalectinsProteolysisgalectin‐3Biochemistry03 medical and health scienceschemistry.chemical_compoundCongenital Disorders of Glycosylation0302 clinical medicineN-linked glycosylationmatrix metalloproteinase-9galectin-3medicineHumansZymographyAmino Acid SequenceProtein precursorMolecular BiologyN‐linked glycosylationEnzyme Precursorspropeptidemedicine.diagnostic_testbiologyBlood ProteinsOriginal ArticlesCell BiologyTrypsinEnzyme Activation030104 developmental biologyMatrix Metalloproteinase 9chemistryBiochemistryGelatinasesCase-Control Studiesproteolytic activation030220 oncology & carcinogenesisNeutrophil elastaseProteolysisbiology.proteinMatrix Metalloproteinase 3Original ArticleLeukocyte Elastasemedicine.drug
researchProduct

Current practice in nutrition after allogeneic hematopoietic stem cell transplantation – Results from a survey among hematopoietic stem cell transpla…

2021

Summary Background Allogeneic hematopoietic stem cell transplantation (alloHSCT) is frequently associated with impaired oral intake and malnutrition, which potentially increases morbidity and mortality. Therefore, nutrition is one of the major challenges in the post-transplant period. Methods To document the current clinical approach in nutritional treatment, we designed a questionnaire concerning the current practice in nutrition after alloHSCT and distributed it to German speaking centers performing alloHSCT in Germany, Austria and Switzerland between November 2018 and March 2020. Twenty-eight (39%) of 72 contacted centers completed the survey, 23 from Germany, two from Austria and three …

0301 basic medicineParenteral Nutritionmedicine.medical_specialtyConsensusNeutropeniamedicine.medical_treatment030209 endocrinology & metabolismHematopoietic stem cell transplantationCritical Care and Intensive Care MedicineNutrition PolicyEating03 medical and health sciences0302 clinical medicineQuality of lifeGermanyInternal medicinemedicineVitamin D and neurologyHumansPractice Patterns Physicians'030109 nutrition & dieteticsNutrition and Dieteticsbusiness.industryBody WeightMalnutritionHematopoietic Stem Cell Transplantationmedicine.diseaseMicronutrientComorbidityDietMalnutritionParenteral nutritionGraft-versus-host diseaseAustriaHealth Care SurveysDietary SupplementsbusinessSwitzerlandClinical Nutrition
researchProduct

Hypertrophic pachymeningitis and cerebral venous thrombosis in myeloperoxidase-ANCA associated vasculitis

2019

Hypertrophic pachymeningitis (HP) is a circumscribed inflammatory process that thickens meninges with fibrous adhesions. Among the causes of HP, vasculitis and autoimmune disease should be considered; myeloperoxidase (MPO)-antinuclear cytoplasmatic antibodies (ANCA)-positivity can be the only

0301 basic medicinePathologymedicine.medical_specialtyImages In…PrednisoloneAnti-Neutrophil Cytoplasmic Antibody-Associated VasculitisANCA-Associated Vasculitis030105 genetics & heredityneurootologyvasculitisAntibodies Antineutrophil Cytoplasmic03 medical and health sciences0302 clinical medicinemedicineHumansskin and connective tissue diseasesPeroxidaseAutoimmune diseaseneuroimagingbiologybusiness.industryHeadacheMeningesmeningitisGeneral MedicineMiddle Agedmedicine.diseaseMagnetic Resonance ImagingVenous thrombosisTreatment Outcomemedicine.anatomical_structureMyeloperoxidasebiology.proteinFemaleSettore MED/26 - NeurologiaIntracranial ThrombosisAntibodyVasculitisbusinessheadache (including migraines)MeningitisBiomarkers030217 neurology & neurosurgeryBMJ Case Reports
researchProduct

Interleukin-17A Promotes Lung Tumor Progression through Neutrophil Attraction to Tumor Sites and Mediating Resistance to PD-1 Blockade

2017

Abstract Introduction Proinflammatory cytokine interleukin-17A (IL-17A) is overexpressed in a subset of patients with lung cancer. We hypothesized that IL-17A promotes a protumorigenic inflammatory phenotype and inhibits antitumor immune responses. Methods We generated bitransgenic mice expressing a conditional IL-17A allele along with conditional Kras G12D and performed immune phenotyping of mouse lungs, a survival analysis, and treatment studies with antibodies either blocking programmed cell death 1 (PD-1) or IL-6 or depleting neutrophils. To support the preclinical findings, we analyzed human gene expression data sets and immune profiled patient lung tumors. Results Tumors in IL-17:Kras…

0301 basic medicinePulmonary and Respiratory MedicineChemokineLung NeoplasmsNeutrophilsLymphocytemedicine.medical_treatmentProgrammed Cell Death 1 ReceptorGene ExpressionMice TransgenicGranulocytemedicine.disease_causeArticleProinflammatory cytokineProto-Oncogene Proteins p21(ras)Mice03 medical and health sciencesImmune systemAnimalsHumansMedicineLung cancerbiologybusiness.industryInterleukin-17medicine.disease030104 developmental biologymedicine.anatomical_structureCytokineOncologyMutationImmunologyDisease Progressionbiology.proteinKRASbusinessJournal of Thoracic Oncology
researchProduct

Trichomonicidal and parasite membrane damaging activity of bidesmosic saponins from Manilkara rufula.

2017

The infection caused by Trichomonas vaginalis is the most common but overlooked non-viral sexually transmitted disease worldwide. Treatment relies on one class of drugs, the 5-nitroimidazoles, but resistance is widespread. New drugs are urgently needed. We reported the effect of crude and purified saponin fractions of Manilkara rufula against Trichomonas vaginalis. The compound responsible for antitrichomonal activity was isolated and identified as an uncommon bidesmosic saponin, Mi-saponin C. This saponin eliminated parasite viability without toxicity against the human vaginal epithelial line (HMVII). In addition, the isolated saponin fraction improved the metronidazole effect against a me…

0301 basic medicineSexually transmitted diseaseNeutrophilsCell MembranesSaponinlcsh:Medicinemedicine.disease_causePathology and Laboratory MedicineBiochemistryMass SpectrometryAnalytical ChemistryWhite Blood CellsOxidative DamageSpectrum Analysis TechniquesAnimal CellsMedicine and Health SciencesParasite hostingElectron Microscopylcsh:Sciencechemistry.chemical_classificationSexually transmitted diseasesTrichomonas VaginalisMicroscopyMultidisciplinaryEukaryotaProtistsMatrix-Assisted Laser Desorption Ionization Mass Spectrometrymusculoskeletal systemChemistryFlagellaToxicityPhysical SciencesVaginaTrichomonasFemaleCellular TypesCellular Structures and OrganellesPathogensMalalties de transmissió sexualIntracellularmedicine.drugResearch ArticlePathogen MotilityEfecte dels medicaments sobre els microorganismesVirulence FactorsImmune CellsImmunologyBiologyResearch and Analysis Methodscomplex mixturesMicrobiologyCell Line03 medical and health sciencesParasite Groupsparasitic diseasesmedicineTrichomonas vaginalisSaponinasHumansTrophozoitesResistència als medicamentsManilkaraBlood CellsCell Membranelcsh:ROrganismsBiology and Life SciencesCell BiologyIntracellular MembranesSaponinsbiology.organism_classificationCell membranescarbohydrates (lipids)MetronidazoleMicroscopy Electron030104 developmental biologychemistryManilkara rufulaDrug resistanceEffect of drugs on microorganismsTrichomonas vaginalisParasitologyTransmission Electron Microscopylcsh:QReactive Oxygen SpeciesApicomplexaMembranes cel·lularsChromatography LiquidPRODUTOS NATURAISPLoS ONE
researchProduct

Sorafenib plus topotecan versus placebo plus topotecan for platinum-resistant ovarian cancer (TRIAS): a multicentre, randomised, double-blind, placeb…

2018

Summary Background Antiangiogenic therapy has known activity in ovarian cancer. The investigator-initiated randomised phase 2 TRIAS trial assessed the multi-kinase inhibitor sorafenib combined with topotecan and continued as maintenance therapy for platinum-resistant or platinum-refractory ovarian cancer. Methods We did a multicentre, double-blind, placebo-controlled, randomised, phase 2 trial at 20 sites in Germany. Patients (≥18 years) with platinum-resistant ovarian cancer previously treated with two or fewer chemotherapy lines for recurrent disease were stratified (first vs later relapse) in block sizes of four and randomly assigned (1:1) using a web-generated response system to topotec…

0301 basic medicineSorafenibAdultmedicine.medical_specialtyTime FactorsPerforation (oil well)Angiogenesis InhibitorsPlatinum CompoundsNeutropeniaPlaceboGastroenterologyDrug Administration Schedule03 medical and health sciences0302 clinical medicineMaintenance therapyDouble-Blind MethodInternal medicineGermanyAntineoplastic Combined Chemotherapy ProtocolsmedicineClinical endpointHumansProgression-free survivalProtein Kinase InhibitorsAgedOvarian Neoplasmsbusiness.industryMiddle AgedSorafenibmedicine.diseaseProgression-Free Survival030104 developmental biologyOncologyDrug Resistance Neoplasm030220 oncology & carcinogenesisDisease ProgressionTopotecanFemaleTopoisomerase I InhibitorsbusinessTopotecanmedicine.drugThe Lancet. Oncology
researchProduct

Formyl-peptide receptor 2 governs leukocyte influx in local Staphylococcus aureus infections

2017

Leukocytes express formyl-peptide receptors (FPRs), which sense microbe-associated molecular pattern (MAMP) molecules, leading to leukocyte chemotaxis and activation. We recently demonstrated that phenol-soluble modulin (PSM) peptides from highly pathogenic Staphylococcus aureus are efficient ligands for the human FPR2. How PSM detection by FPR2 impacts on the course of S. aureus infections has remained unknown. We characterized the specificity of mouse FPR2 (mFpr2) using a receptor-transfected cell line, homeobox b8 (Hoxb8), and primary neutrophils isolated from wild-type (WT) or mFpr2−/− mice. The influx of leukocytes into the peritoneum of WT and mFpr2−/− mice was analyzed. We demonstrat…

0301 basic medicineStaphylococcus aureusNeutrophilsBacterial Toxinsmedicine.disease_causeLigandsBiochemistryCell DegranulationFormyl peptide receptor 2MicrobiologyCell Line03 medical and health sciencesMice0302 clinical medicinePeritoneumCell MovementGeneticsmedicineLeukocytesAnimalsHumansCalcium SignalingReceptors LipoxinReceptorMolecular BiologyHomeodomain ProteinsMice KnockoutInnate immune systemChemistryResearchHOXB8Staphylococcal InfectionsReceptors Formyl PeptideMice Inbred C57BLDisease Models Animal030104 developmental biologymedicine.anatomical_structureCell cultureStaphylococcus aureusGenes BacterialMutationFemaleLeukocyte chemotaxis030215 immunologyBiotechnology
researchProduct

Thrombo-Inflammation in Cardiovascular Disease

2020

AbstractThrombo-inflammation describes the complex interplay between blood coagulation and inflammation that plays a critical role in cardiovascular diseases. The third Maastricht Consensus Conference on Thrombosis assembled basic, translational, and clinical scientists to discuss the origin and potential consequences of thrombo-inflammation in the etiology, diagnostics, and management of patients with cardiovascular disease, including myocardial infarction, stroke, and peripheral artery disease. This article presents a state-of-the-art reflection of expert opinions and consensus recommendations regarding the following topics: (1) challenges of the endothelial cell barrier; (2) circulating …

0301 basic medicineVENOUS THROMBOSISmedicine.medical_specialtypulmonary embolismNeutrophilsIschemiaISCHEMIA-REPERFUSION INJURYDisease030204 cardiovascular system & hematologyCATHETER-DIRECTED THROMBOLYSIS03 medical and health sciences0302 clinical medicinePERIPHERAL ARTERY-DISEASEMedicineAnimalsHumansPlateletMyocardial infarctionDEEP-VEIN THROMBOSIScoagulationIntensive care medicineStrokeBlood CoagulationExpert Testimonythrombosisbusiness.industryACUTE CORONARY SYNDROMESNEUTROPHIL EXTRACELLULAR TRAPSHematologyNeutrophil extracellular trapsVenous ThromboembolismACTIVATABLE FIBRINOLYSIS INHIBITORmedicine.diseaseAtherosclerosisThrombosisstrokeImmunity Innate3. Good healthVenous thrombosis030104 developmental biologymyocardial infarctionTISSUE FACTORCardiovascular DiseasesinflammationplateletsEndothelium VascularbusinessSUBCLINICAL LEAFLET THROMBOSISThrombosis and Haemostasis
researchProduct